BZUN vs POM
Baozun Inc. and Pomdoctor Limited, side by side — 3 fiscal years reported in CNY, drawn from SEC filings.
At a glance
Most recent reported year
| Metric | BZUN | POM |
|---|---|---|
| Revenue | ¥9.9B | ¥399.9M |
| Net income | ¥-242.1M | ¥-130.9M |
| Gross margin | 74.1% | 13.1% |
| Net margin | −2.4% | −32.7% |
| Return on equity | −6.4% | — |
| Diluted EPS | −¥1.40 | −¥21.96 |
| Dividend / share | — | — |
| Payout ratio | −9.2% | — |
| Free cash flow | ¥313.9M | ¥-149.5M |
| Equity | ¥3.6B | ¥-454.0M |
| Net debt / equity | 0.08× | — |
| Current ratio | 1.87× | 0.48× |
| Revenue CAGR 5y | 2.4% | — |
| Profit CAGR 5y | — | — |
BZUN bills 24.9× the revenue of POM, and both closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner.
Advertisement
AdSense · Leaderboard 728×90 · responsive
Revenue by year
3 years side by side
| Fiscal year | BZUN | POM |
|---|---|---|
| FY2025 | ¥9.9B | ¥399.9M |
| FY2024 | ¥9.4B | ¥342.6M |
| FY2023 | ¥8.8B | ¥304.9M |
Net income by year
Bottom line
| Fiscal year | BZUN | POM |
|---|---|---|
| FY2025 | ¥-242.1M | ¥-130.9M |
| FY2024 | ¥-185.2M | ¥-37.4M |
| FY2023 | ¥-278.4M | ¥-36.9M |
Advertisement
AdSense · Rectangle 336×280
More in this industry